TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
doctor examines patient data on their tablet

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

ACC.24 late-breaking clinical trials

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

Newsweek ranked the 50 best heart hospitals in the world

Moderate prosthesis-patient mismatch after SAVR linked to worse long-term outcomes

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

New risk score helps cardiologists predict when TAVR patients may require dialysis

Patients who need renal replacement therapy after TAVR are much less likely to survive. Researchers hope their new risk score can help care teams prepare ahead of time for this rare, but potentially fatal complication. 

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

FDA approves Medtronic’s next-generation TAVR system with new frame design

The Evolut FX+ TAVR system includes an updated diamond-shaped frame, which was made four times larger than previous models to offer improved coronary access. It was also designed to provide more space for operators to guide and maneuver the catheter during procedures.

Heart attacks after TAVR: New AMI data ‘reassuring’ at first glance, but questions remain

Hoping to gain a better understanding of how TAVR may impact a patient’s long-term cardiovascular health, researchers explored data from more than 200,000 patients and shared their findings in JACC: Cardiovascular Interventions.

doctor comparing the costs of different medical treatments

TAVR is often more cost-effective than SAVR—but not always

Average lengths of stay and common complications are just some of the factors care teams should consider when evaluating the costs of aortic valve replacement. 

Displaying 81 - 88 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.